Brain Reactivity to Smoking Cues Prior to Smoking Cessation Predicts Ability to Maintain Tobacco Abstinence

Abstract
No abstract available
Funding Information
  • National Institute on Drug Abuse (U01DA019378, R01DA022276, R01DA014674, R01DA09448, K02DA017324, T32DA015036)
  • Counter-Drug Technology Assessment Center
  • GlaxoSmithKline
  • GlaxoSmithKline and ANT North America, Inc.
  • Abbott Laboratories
  • Alkermes
  • Aspect Medical Systems
  • AstraZeneca
  • Bio Research
  • BrainCells, Inc.
  • Bristol-Myers Squibb Company
  • Cephalon
  • Clinical Trial Solutions
  • Eli Lilly and Company
  • Forest Pharmaceuticals, Inc.
  • Ganeden
  • GlaxoSmithKline
  • J and J Pharmaceuticals
  • Lichtwer Pharma
  • GmBH
  • Lorex Pharmaceuticals
  • National Alliance for Research on Schizophrenia and Depression
  • National Center for Complementary and Alternative Medicine
  • National Institute on Drug Abuse
  • National Institute of Mental Health
  • Novartis
  • Organon, Inc.
  • PamLab
  • LLC
  • Pfizer, Inc.
  • Pharmavite
  • Roche
  • Sanofi-Aventis
  • Shire, Solvay Pharmaceuticals, Inc.
  • Synthelabo
  • Wyeth-Ayerst Laboratories